Oragenics, Inc. announced in August 2024 that its lead drug candidate, ONP-002, successfully completed FDA-required genotoxicity testing. These studies confirmed that the drug does not cause DNA damage.
This achievement further strengthens the safety profile of ONP-002 as it advances towards Phase II clinical trials. Demonstrating a lack of genotoxicity is a critical regulatory requirement for drug development.
The successful completion of these safety studies is an important de-risking event for the ONP-002 program. It supports the company's efforts to develop a novel treatment for concussions.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.